Sun Pharma launches Ilumya for psoriasis treatment in India

India’s largest drug maker Sun Pharmaceutical Industries has launched its global innovative drug Ilumya (tildrakizumab) in the country, the company said in an announcement on Monday.

Ilumya is used in the treatment of plaque psoriasis.

“Ilumya offers a safe and effective treatment option for patients who are struggling to manage their moderate-to-severe plaque psoriasis,” said Kirti Ganorkar, managing director, Sun Pharma.


Already available in 35 countries, Ilumya has demonstrated significant and long-lasting skin clearance, he said.

Sun Pharma’s clinical study in India included 115 patients of moderate-to-severe plaque psoriasis. A 75% skin clearance was seen in 62.3%, 83.3% and 93.9% patients, respectively, at week 12, 16 and 28. A 90% skin clearance was seen in 26.3%, 50% and 78.1% patients, respectively, at week 12, 16 and 28.

Patients received three subcutaneous injections of tildrakizumab over a period of 16 weeks and were followed for a period of 28 weeks.